Drug Profile
CGH 2466
Latest Information Update: 17 Apr 2002
Price :
$50
*
At a glance
- Originator Novartis
- Class Anti-inflammatories
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors; Purinergic P1 receptor antagonists; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 17 Apr 2002 No development reported - Preclinical for Asthma in Switzerland (Intranasal)
- 17 Apr 2002 No development reported - Preclinical for Asthma in United Kingdom (Intranasal)
- 17 Apr 2002 No development reported - Preclinical for Chronic obstructive pulmonary disease in Switzerland (Intranasal)